Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Matthews

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Evidence-Based Medicine|March 24, 2011
Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD studyDavid R Matthews
Lancet (London, England)|October 24, 2017
Junior hospital doctors-time to rethink the terminologyDavid R Matthews
Diabetes & Vascular Disease Research|March 16, 2012
Cardiovascular trials and diabetes treatments: a regulatory mazeDavid R Matthews
Diabetes, Obesity & Metabolism|September 28, 2024
Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetesDavid R Matthews
Diabetes, Obesity & Metabolism|April 7, 2020
ADVANCEDavid R Matthews
Diabetes, Obesity & Metabolism|October 31, 2001
Insulin resistance and beta-cell function - a clinical perspectiveDavid R. Matthews
Lancet (London, England)|December 4, 2003
Diabetes and the global burden of non-communicable diseaseDavid R Matthews, Stig Pramming
Diabetes & Vascular Disease Research|September 9, 2008
Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetesDavid R Matthews, Apostolos Tsapas
JAMA|March 13, 2009
Using N-of-1 trials in evidence-based clinical practiceApostolos Tsapas, David R Matthews
Lancet (London, England)|June 12, 2009
Impending type 2 diabetesDavid R Matthews, Jonathan C Levy
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Evidence-Based Medicine|March 24, 2011
Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD studyDavid R Matthews
Lancet (London, England)|October 24, 2017
Junior hospital doctors-time to rethink the terminologyDavid R Matthews
Diabetes & Vascular Disease Research|March 16, 2012
Cardiovascular trials and diabetes treatments: a regulatory mazeDavid R Matthews
Diabetes, Obesity & Metabolism|September 28, 2024
Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetesDavid R Matthews
Diabetes, Obesity & Metabolism|April 7, 2020
ADVANCEDavid R Matthews
Diabetes, Obesity & Metabolism|October 31, 2001
Insulin resistance and beta-cell function - a clinical perspectiveDavid R. Matthews
Lancet (London, England)|December 4, 2003
Diabetes and the global burden of non-communicable diseaseDavid R Matthews, Stig Pramming
Diabetes & Vascular Disease Research|September 9, 2008
Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetesDavid R Matthews, Apostolos Tsapas
JAMA|March 13, 2009
Using N-of-1 trials in evidence-based clinical practiceApostolos Tsapas, David R Matthews
Lancet (London, England)|June 12, 2009
Impending type 2 diabetesDavid R Matthews, Jonathan C Levy
Pageof 12